secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0000950170-25-061994
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics updates corporate presentation on 212Pb radiopharmaceutical pipeline
--------------------------------------------------------------------------------

- Neuroendocrine tumor trial VMT-α-NET Phase 1/2a shows sustained anti-tumor activity and good tolerability; no renal function decline observed.
- Metastatic melanoma program VMT01/02 Phase 1/2a dosing ongoing; treatment-emergent AEs summarized in presentation.
- PSV359 Phase 1/2a targets FAP-α expression on tumor and stroma.
- Platform uses proprietary chelator optimized for lead-212 RPTs and on-demand regional manufacturing infrastructure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017025061994/0000950170-25-061994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017025061994/catx-20250501.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-061994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer